Evidence map›Paper›PMID 42100870›Full record

ArticleJCI insight2026

Progressive HNF1A-MODY pathophysiology revealed by a translational mouse model.

Isaline Louvet, Ana Acosta-Montalvo, Chiara Saponaro, Maria Moreno-Lopez, Sana Douffi, Abdelkrim El Karchaoui, Gianni Pasquetti, Julien Thevenet, Nathalie Delalleau, Valery Gmyr and 6 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Isaline LouvetUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Ana Acosta-MontalvoUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Chiara SaponaroUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Maria Moreno-LopezUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Sana DouffiUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Abdelkrim El KarchaouiUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Gianni PasquettiUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Julien ThevenetUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Nathalie DelalleauUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Valery GmyrUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Paolo GiacobiniLaboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 Days for Health, School of Medicine, Lille, France.
Stéphanie EspiardUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Julie Kerr-ConteUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
François PattouUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
Adrian ListonDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.
Caroline BonnerUniversity of Lille, CHU Lille, Inserm U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HNF1A-MODY, the most common monogenic diabetes, exhibits progressive β cell dysfunction, but existing mouse models fail to recapitulate human disease progression, limiting understanding of pathogenic mechanisms. We developed mice with heterozygous deletion of the Hnf1a transactivation domain (Hnf1a+/Δe4-10) to model human HNF1A haploinsufficiency, conducted cross-sectional metabolic characterization, and validated our findings in HNF1A-deficient human islets. Unlike previous models, Hnf1a+/Δe4-10 mice successfully recapitulated temporal HNF1A-MODY progression. Male mice developed sequential pathophysiology: early insulin resistance in young adults (7 weeks), followed by testosterone deficiency and fasting hyperglycemia in adult mice (10 weeks). Glucose intolerance emerged in middle-aged mice (30 weeks), progressing to multi-organ dysfunction in aged mice (44-70 weeks), characterized by elevated hepatic gluconeogenesis, impaired renal glucose handling, and hepatic steatosis/fibrosis. This dual pathophysiology involving β cell dysfunction and peripheral insulin resistance was associated with dysregulated hormone secretion from both α and β cells in aged mice (40-70 weeks). Human islet studies with HNF1A knockdown confirmed translational relevance, demonstrating reduced SGLT2 protein expression and inappropriate glucagon and insulin secretion. This work established a physiologically relevant HNF1A-MODY model, identified early insulin resistance as a key mechanism triggering hormonal dysfunction, and revealed HNF1A's role in multi-organ pathophysiology beyond traditional β cell dysfunction.

Indexed as

Diabetes Mellitus, Type 2Hepatocyte Nuclear Factor 1-alphaAnimalsDisease Models, AnimalDisease ProgressionGlucose IntoleranceHumansInsulinInsulin ResistanceInsulin-Secreting CellsLiverMaleMiceHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanHnf1a protein, mouseInsulinAgingBeta cellsDiabetesEndocrinologyMetabolism

Identifiers

PMID42100870
PMCPMC13232485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.